M&A · Healthcare · Buyer's industry: Services-Medical Laboratories
Fulgent Genetics, Inc. to acquire Bako Diagnostics and StrataDx
Announced Dec 22, 2025 · Closed Mar 17, 2026 · Private target
Deal value—
Premium—To unaffected price
EV / Adj. EBITDA—
ConsiderationAll cash
Transaction
- Acquirer
- Fulgent Genetics, Inc. (FLGT)
- Target
- Bako Diagnostics and StrataDx
- Buyer type
- Strategic
- Offer price per share
- —
- Enterprise value
- —
- Status
- Closed Mar 17, 2026
Deal protections
Not disclosed for private-company acquisitions.
Advisors
- To the acquirer
- Piper Sandler
- To the target
- Not disclosed
Classification
- Sector
- Healthcare
- Buyer's industry
- Services-Medical Laboratories